Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study

Chia Ling Li, Te-Chun Hsia, Chia Hsiang Li, Ko Jung Chen, Yao Hsu Yang, Su Tso Yang

Research output: Contribution to journalArticle

Abstract

Objectives: The clinical effect of traditional Chinese medicine (TCM) on survival in patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a major concern and requires more evidence from large-scale clinical studies. Materials and Methods: This population-based cohort study used the Taiwan National Health Insurance Research Database to enroll patients between 2006 and 2012 who had newly diagnosed locally advanced and metastatic lung adenocarcinoma treated with first-line gefitinib or erlotinib. Survival was tracked until 2013. The patients were separated into TCM users and nonusers, and Cox regression models were applied to determine the association between the use of TCM and the survival of patients. Results: A total of 1988 patients receiving first-line gefitinib or erlotinib for the treatment of EGFR-mutated advanced lung adenocarcinoma, with the exclusion of TCM users after tumor progression, were included in this cohort study. Compared with TCM nonuse, TCM use for ≥180 days was associated with a significantly decreased risk of mortality by 68% (adjusted hazard ratio [HR], 0.32 [95% CI, 0.21-0.50], P <.0001). Compared with TCM nonuse, TCM use for ≥180 days was associated with a significantly decreased risk of disease progression by 59% (adjusted HR, 0.41 [95% CI, 0.29-0.58], P <.0001). Conclusion: This cohort study suggests that adjunctive TCM therapy could improve overall survival and progression-free survival in patients with advanced lung adenocarcinoma treated with first-line TKIs. Future randomized, controlled trials are required to validate these findings.

Original languageEnglish (US)
JournalIntegrative cancer therapies
Volume18
DOIs
StatePublished - Feb 1 2019

Fingerprint

Chinese Traditional Medicine
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Cohort Studies
Survival
Population
Adenocarcinoma of lung
National Health Programs
Taiwan
Proportional Hazards Models
Disease-Free Survival
Disease Progression
Randomized Controlled Trials
Databases
Mortality
Therapeutics

Keywords

  • advanced lung adenocarcinoma
  • EGFR-TKI
  • National Health Insurance Research Database
  • overall survival
  • progression-free survival
  • traditional Chinese medicine

ASJC Scopus subject areas

  • Oncology
  • Complementary and alternative medicine

Cite this

@article{63afe05b17ff4622bb5e4f7c66ebf4db,
title = "Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study",
abstract = "Objectives: The clinical effect of traditional Chinese medicine (TCM) on survival in patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a major concern and requires more evidence from large-scale clinical studies. Materials and Methods: This population-based cohort study used the Taiwan National Health Insurance Research Database to enroll patients between 2006 and 2012 who had newly diagnosed locally advanced and metastatic lung adenocarcinoma treated with first-line gefitinib or erlotinib. Survival was tracked until 2013. The patients were separated into TCM users and nonusers, and Cox regression models were applied to determine the association between the use of TCM and the survival of patients. Results: A total of 1988 patients receiving first-line gefitinib or erlotinib for the treatment of EGFR-mutated advanced lung adenocarcinoma, with the exclusion of TCM users after tumor progression, were included in this cohort study. Compared with TCM nonuse, TCM use for ≥180 days was associated with a significantly decreased risk of mortality by 68{\%} (adjusted hazard ratio [HR], 0.32 [95{\%} CI, 0.21-0.50], P <.0001). Compared with TCM nonuse, TCM use for ≥180 days was associated with a significantly decreased risk of disease progression by 59{\%} (adjusted HR, 0.41 [95{\%} CI, 0.29-0.58], P <.0001). Conclusion: This cohort study suggests that adjunctive TCM therapy could improve overall survival and progression-free survival in patients with advanced lung adenocarcinoma treated with first-line TKIs. Future randomized, controlled trials are required to validate these findings.",
keywords = "advanced lung adenocarcinoma, EGFR-TKI, National Health Insurance Research Database, overall survival, progression-free survival, traditional Chinese medicine",
author = "Li, {Chia Ling} and Te-Chun Hsia and Li, {Chia Hsiang} and Chen, {Ko Jung} and Yang, {Yao Hsu} and Yang, {Su Tso}",
year = "2019",
month = "2",
day = "1",
doi = "10.1177/1534735419827079",
language = "English (US)",
volume = "18",
journal = "Integrative Cancer Therapies",
issn = "1534-7354",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)

T2 - A Nationwide, Population-Based Cohort Study

AU - Li, Chia Ling

AU - Hsia, Te-Chun

AU - Li, Chia Hsiang

AU - Chen, Ko Jung

AU - Yang, Yao Hsu

AU - Yang, Su Tso

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Objectives: The clinical effect of traditional Chinese medicine (TCM) on survival in patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a major concern and requires more evidence from large-scale clinical studies. Materials and Methods: This population-based cohort study used the Taiwan National Health Insurance Research Database to enroll patients between 2006 and 2012 who had newly diagnosed locally advanced and metastatic lung adenocarcinoma treated with first-line gefitinib or erlotinib. Survival was tracked until 2013. The patients were separated into TCM users and nonusers, and Cox regression models were applied to determine the association between the use of TCM and the survival of patients. Results: A total of 1988 patients receiving first-line gefitinib or erlotinib for the treatment of EGFR-mutated advanced lung adenocarcinoma, with the exclusion of TCM users after tumor progression, were included in this cohort study. Compared with TCM nonuse, TCM use for ≥180 days was associated with a significantly decreased risk of mortality by 68% (adjusted hazard ratio [HR], 0.32 [95% CI, 0.21-0.50], P <.0001). Compared with TCM nonuse, TCM use for ≥180 days was associated with a significantly decreased risk of disease progression by 59% (adjusted HR, 0.41 [95% CI, 0.29-0.58], P <.0001). Conclusion: This cohort study suggests that adjunctive TCM therapy could improve overall survival and progression-free survival in patients with advanced lung adenocarcinoma treated with first-line TKIs. Future randomized, controlled trials are required to validate these findings.

AB - Objectives: The clinical effect of traditional Chinese medicine (TCM) on survival in patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a major concern and requires more evidence from large-scale clinical studies. Materials and Methods: This population-based cohort study used the Taiwan National Health Insurance Research Database to enroll patients between 2006 and 2012 who had newly diagnosed locally advanced and metastatic lung adenocarcinoma treated with first-line gefitinib or erlotinib. Survival was tracked until 2013. The patients were separated into TCM users and nonusers, and Cox regression models were applied to determine the association between the use of TCM and the survival of patients. Results: A total of 1988 patients receiving first-line gefitinib or erlotinib for the treatment of EGFR-mutated advanced lung adenocarcinoma, with the exclusion of TCM users after tumor progression, were included in this cohort study. Compared with TCM nonuse, TCM use for ≥180 days was associated with a significantly decreased risk of mortality by 68% (adjusted hazard ratio [HR], 0.32 [95% CI, 0.21-0.50], P <.0001). Compared with TCM nonuse, TCM use for ≥180 days was associated with a significantly decreased risk of disease progression by 59% (adjusted HR, 0.41 [95% CI, 0.29-0.58], P <.0001). Conclusion: This cohort study suggests that adjunctive TCM therapy could improve overall survival and progression-free survival in patients with advanced lung adenocarcinoma treated with first-line TKIs. Future randomized, controlled trials are required to validate these findings.

KW - advanced lung adenocarcinoma

KW - EGFR-TKI

KW - National Health Insurance Research Database

KW - overall survival

KW - progression-free survival

KW - traditional Chinese medicine

UR - http://www.scopus.com/inward/record.url?scp=85062584564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062584564&partnerID=8YFLogxK

U2 - 10.1177/1534735419827079

DO - 10.1177/1534735419827079

M3 - Article

VL - 18

JO - Integrative Cancer Therapies

JF - Integrative Cancer Therapies

SN - 1534-7354

ER -